| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/01/2009 | EP2040687A1 Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine |
| 04/01/2009 | EP2040686A1 Methods of using a thiazole derivative |
| 04/01/2009 | EP2040685A2 Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means |
| 04/01/2009 | EP2040683A1 Pharmaceutical composition containing a tetrahydrofolic acid |
| 04/01/2009 | EP2040681A2 Improvements relating to pharmaceutical compositions |
| 04/01/2009 | EP2040680A2 Improvements relating to pharmaceutical compositions |
| 04/01/2009 | EP2040678A2 Improvements relating to biocidal compositions |
| 04/01/2009 | EP2040677A2 Improvements relating to anti-parasitic compositions |
| 04/01/2009 | EP2040676A2 Orally dissolving formulations of memantine |
| 04/01/2009 | EP2040674A1 Cationic liposomal preparations for the treatment of rheumatoid arthritis |
| 04/01/2009 | EP2040672A2 Enhanced stability phenylephrine liquid compositions |
| 04/01/2009 | EP2040671A2 Aqueous suspensions of tmc278 |
| 04/01/2009 | EP2040670A1 Stable aerosol pharmaceutical formulations |
| 04/01/2009 | EP2040566A1 Milk fever |
| 04/01/2009 | EP2040564A1 Zilpaterol enantiomer compositions and methods of making and using such compositions |
| 04/01/2009 | EP2040549A2 Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor |
| 04/01/2009 | EP2040548A2 Method for the treatment of neurological disorders by enhancing the activity of beta -glucocerebrosidase |
| 04/01/2009 | EP2040546A2 Tyrosine kinase inhibitors |
| 04/01/2009 | EP2040544A2 Method of inhibiting the transmission of viruses |
| 04/01/2009 | EP2040541A1 Adjuvants and methods of use |
| 04/01/2009 | EP1924259A4 Inhibition of intermediate-conductance calcium activated potassium channels in the treatment and/or prevention of atherosclerosis |
| 04/01/2009 | EP1845780A4 Uses of methylphenidate derivatives |
| 04/01/2009 | EP1836151B1 Vitamin d receptor modulators |
| 04/01/2009 | EP1835916B1 Compounds useful in the treatment of hiv |
| 04/01/2009 | EP1828141A4 A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o |
| 04/01/2009 | EP1773770B1 Indole-2-carboxamidine derivatives as nmda receptor antagonists |
| 04/01/2009 | EP1768987B1 (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions |
| 04/01/2009 | EP1755585A4 Transthyretin stabilization |
| 04/01/2009 | EP1702612B1 Soft capsule containing butylphthalide and its preparation procedure |
| 04/01/2009 | EP1673348B1 Benzoimidazole compounds |
| 04/01/2009 | EP1664012B1 Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics |
| 04/01/2009 | EP1660431B1 Phenoxyacetic acid derivatives |
| 04/01/2009 | EP1653961A4 Inhibitors of akt activity |
| 04/01/2009 | EP1620429B1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 04/01/2009 | EP1532248B1 Modified small interfering rna molecules and methods of use |
| 04/01/2009 | EP1521744B1 Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists |
| 04/01/2009 | EP1513530A4 Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 04/01/2009 | EP1506175B1 N-substituted tricyclic 3-aminopyrazoles as pdgf receptor inhibitors |
| 04/01/2009 | EP1473295B1 Fused bicyclic pyrimidine derivatives |
| 04/01/2009 | EP1472375B1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 04/01/2009 | EP1467720B1 Dna dosage forms |
| 04/01/2009 | EP1465640B8 Use of polysaccharide derivatives as anti-infective substances |
| 04/01/2009 | EP1458388B1 A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity |
| 04/01/2009 | EP1450804B9 Pharmaceutical formulations comprising an immune response modifier |
| 04/01/2009 | EP1427825B1 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 04/01/2009 | EP1425582B1 Diagnostic markers for ischemia and risk of mortaility |
| 04/01/2009 | EP1392669B1 Chromatographic separation method of paclitaxel and cephalomannin |
| 04/01/2009 | EP1349873B1 Modulation of il-2- and il-15-mediated t cell responses |
| 04/01/2009 | EP1294379B1 A new use for deferiprone |
| 04/01/2009 | EP1126828B1 Oral administration of adenosine analogs |
| 04/01/2009 | EP1123087B1 Oral pulsed dose drug delivery system |
| 04/01/2009 | EP1082308B1 Heterocyclically substituted amides used as calpain inhibitors |
| 04/01/2009 | EP1038879B1 Drugs, foods or drinks with the use of algae-derived physiologically active substances |
| 04/01/2009 | EP0888386B2 Stable, virus-safe factor VIII-complex concentrate |
| 04/01/2009 | CN101400697A Prevention/treatment of ichthyosis vulgaris, atopy and other disorders |
| 04/01/2009 | CN101400690A Modulators of hypoxia inducible factor-1 and related uses |
| 04/01/2009 | CN101400684A Thiazole compound |
| 04/01/2009 | CN101400683A Process for the preparation of olanzapine |
| 04/01/2009 | CN101400681A Substituted indazole derivatives, their manufacture and use as pharmaceutical agents |
| 04/01/2009 | CN101400678A Thiophene-carboxamides useful as inhibitors of protein kinases |
| 04/01/2009 | CN101400677A Compounds |
| 04/01/2009 | CN101400676A Tropane prodrugs with central nervous system activity |
| 04/01/2009 | CN101400675A Novel enantiomerically pure beta-agonists, method for their production and their use as medicaments |
| 04/01/2009 | CN101400674A Antibiotic compounds |
| 04/01/2009 | CN101400673A Heterobicyclic carboxamides as inhibitors for kinases |
| 04/01/2009 | CN101400672A Pyrazolylquinazolinones as potassium channel openers |
| 04/01/2009 | CN101400671A Substituted prolinamides, their preparation and their use as pharmaceuticals |
| 04/01/2009 | CN101400670A Novel pyridine derivative having anti-helicobacter pylori activity |
| 04/01/2009 | CN101400669A Benzimidazole derivatives |
| 04/01/2009 | CN101400663A Polymorphic forms of { 2-methyl-4- [4-methyl-2- (trifluoromethylphenyl) thiazol-5-methylthiol phenoxy}-acetic acid |
| 04/01/2009 | CN101400660A Triazole derivative or salt thereof |
| 04/01/2009 | CN101400659A Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
| 04/01/2009 | CN101400658A Photoactive compounds and compositions and uses thereof |
| 04/01/2009 | CN101400657A Polycyclic cinnamide derivative |
| 04/01/2009 | CN101400656A Piperazine derivatives as farnesyl protein transferase inhibitors |
| 04/01/2009 | CN101400655A Quinolone derivative or pharmaceutically acceptable salt thereof |
| 04/01/2009 | CN101400654A 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors |
| 04/01/2009 | CN101400653A 11-beta HSD1 inhibitors |
| 04/01/2009 | CN101400652A Use of tetrahydropyridines in the treatment of central nervous system disorders |
| 04/01/2009 | CN101400642A Tropane prodrugs with central nervous system activity |
| 04/01/2009 | CN101400407A Tropane prodrugs with central nervous system activity |
| 04/01/2009 | CN101400362A Bifunctional histone deacetylase inhibitors |
| 04/01/2009 | CN101400360A Phospholipid complexes of curcumin having improved bioavailability |
| 04/01/2009 | CN101400357A Method for treating oncological diseases |
| 04/01/2009 | CN101400356A Treatment of acute respiratory distress syndrome |
| 04/01/2009 | CN101400355A Ophthalmic compositions comprising povidone-iodine |
| 04/01/2009 | CN101400354A Aqueous composition |
| 04/01/2009 | CN101400353A Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders |
| 04/01/2009 | CN101400352A Compositions and methods for the treatment and prevention of disease |
| 04/01/2009 | CN101400351A Medicament formulations comprising fluoroquinolones |
| 04/01/2009 | CN101400350A Serotonergic agents for treating sexual dysfunction |
| 04/01/2009 | CN101400349A Compounds for inhibiting beta-amyloid production |
| 04/01/2009 | CN101400348A Tetrahydroisoquinoline derivatives to enhance memory function |
| 04/01/2009 | CN101400347A Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea |
| 04/01/2009 | CN101400346A Pharmaceutical combination composition comprising at least one PKC inhibitor and at least one JAK3 kinase inhibitor for treating autoimmune disorders |
| 04/01/2009 | CN101400345A Cardioplegic solution |
| 04/01/2009 | CN101400344A Composition for improving cellular membrane composition and function |
| 04/01/2009 | CN101400342A Controlled release formulation of divalproic acid and its derivatives |
| 04/01/2009 | CN101400339A Formulations of sitaxsentan sodium |
| 04/01/2009 | CN101400335A Central administration of stable formulations of therapeutic agents for CNS conditions |